Nippon Shinyaku, Jeil-Kirin Conclude Licensing Agreement

Kirin Brewery announced that its group company in Korea, Jeil-Kirin Pharmaceutical, has concluded a licensing agreement with Nippon Shinyaku for TRISENOX Injection 10 mg, an agent used in the treatment of relapsed and refractory Acute Promyelocytic Leukemia (APL), a distinct subtype of acute myelocytic leukemia. Under the terms of the agreement, Jeil-Kirin Pharmaceutical will exclusively sell TRISENOX Injection in Korea. Jeil-Kirin Pharmaceutical plans to launch the agent in 2006.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=10104)